Dr. Vikash Mishra

Dr. Vikash Mishra

Researcher

Chimera Transplant Research Foundation

Profile ID RP-002-6670 Joined 2024-04-20 58 articles
0Connections
10
Total Views
58
Total Publications
990
Publication Views

About me

Over 15 years of experience in histocompatibility, DNA profiling, and laboratory quality management and accreditation.

Articles(58)

Authors: Vikash C. Mishra, Dinesh Chandra, Parvind Singh, Trupti Deshpande, Pranav Dorwal, Vimarsh Raina

DOI: 10.1111/voxs.12502

Volume14
Issue4
Pages374-378
Abstract

Background and ObjectivesTimely detection of human leucocyte antigen (HLA) antibodies plays a key part in transplant outcome. Conventionally, several cell‐based assays are available for detection of HLA antibodies upgrading to virtual crossmatch in which single‐antigen bead (SAB) assay is widely used for characterization of pre‐formed HLA donor‐specific antibodies (DSAs). The main objective here is to find the prevalence and specificity of anti‐HLA antibodies in Indian population using Luminex single‐antigen (LSA) bead assay.Materials and MethodsA total of 179 patients are included in the study for analysing anti‐HLA antibodies by Luminex bead assays that comprise a panel of beads coated with purified HLA antigens (both class I and class II).ResultsHLA‐A*24:02, HLA‐A*02:02, HLA‐B*15:02 and HLA‐B*27:08 and HLA‐C*07:01, HLA‐C*07:02 and HLA‐C*06:02 are frequently identified HLA antibodies against class I, whereas HLA‐DRB1*09:01, HLA‐DRB3*01:01, HLA‐DQA1*01:02, HLA‐DQB1*06:04, HLA‐DQA1*05:01, HLA‐DQB1*03:01, HLA‐DPA1*02:01, HLA‐DPB1*14:01, HLA‐DPA1*01:03 and HLA‐DPB1*18:01 are most common anti‐HLA antibodies against class II.ConclusionsTo conclude, this study helps to select the population‐specific best possible donor and hence improve transplant outcome to decrease risk of antibody‐mediated rejection.

Authors: Vikash Chandra Mishra, Pranav Dorwal, Hina Solanki, Tarun Kohli, Aseem Kumar Tiwari, Vimarsh Raina, Girish Sharma

DOI: 10.4103/ijmpo.ijmpo_3_18

Volume40
Issue1
Pages32-34
Abstract

Abstract Introduction: Human leukocyte antigen (HLA)-matched unrelated donor (MUD) is the source of MUD transplantation (MUDT) for about 70% of patients who do not have matched related donor. To facilitate MUD search globally, there are 75 stem cell registries with more than 28 million donors registered (as of January 2017). Out of these donors, India has an insignificant representation of approximately 0.23 million. Further, Indians express high genetic variations, making it difficult to find MUD for an Indian patient. Aims and Objectives: The aim of this study is to analyze the MUD search for hematological disorder patients requiring transplant. An attempt was made to observe the MUD scenario for Indian patients requiring MUDT from accessible stem cell registries. Methods: A total of 558 patients approached Genebandhu registry and Chimera Transplant Research Foundation for MUD search over a period of 4 years requiring MUDT were included in this study. High resolution of HLA-A, -B, -C, -DRB1, and -DQB1 was used to perform MUD search through proprietary software called Prometheus and Bone Marrow Donors Worldwide (BMDW) search tool. Results: Out of 558 patients, MUD was located only for 135 (24.19%) patients. Out of these 135 patients, 91 (16.30%) patients found an MUD in global database and only 44 (7.88%) patients within India. Conclusion: This study demonstrates that building a large Indian database will not only help in increasing the chances of finding an MUD for maximum number of patients within India but also provide cost-effective treatment, in a society where cost is a vital factor.

Authors: Hina Solanki, Vikash C. Mishra, Aseem K. Tiwari, Nipun Kakkar, Naveen Vashisht, Vimarsh Raina, Girish Sharma

DOI: 10.4103/ijmpo.ijmpo_195_20

Volume41
Issue6
Pages850-858
Abstract

Abstract Objective: Acute lymphoid leukemia (ALL) and acute myeloid leukemia (AML) are neoplastic blood disorders in which the cancerous white blood cells accumulate, resulting in a significant morbidity and mortality. Human leukocyte antigen (HLA) association is observed as one of the factors in the development of leukemia. The objective of the present study was to analyze the allele frequency of HLA Class I (HLA-A, HLA-B, and HLA-C) and Class II (HLA-DRB1 and HLA-DQB1) in Indian acute leukemia patients and to compare them with the frequencies in healthy, unrelated Indian individuals. Materials and Methods: We included 500 Indian leukemic patients (AML = 324 and ALL = 176) and 1000 unrelated, healthy, Indian individuals as controls. The HLA typing was performed using polymerase chain reaction with sequence-specific oligonucleotide probes. Results: On univariate analysis, allele frequencies of HLA-AFN*0111 and HLA-DRB1FN*0111 were lower in patients with ALL (P = 0.0181 and P = 0.0025, respectively). Whereas of HLA-AFN*0111, HLA-DRB1FN*0111, and HLA-BFN*0151, these frequencies were relatively lower in patients with acute leukemia (AML + ALL) (P = 0.0382, P = 0.0093 and P = 0.0384, respectively) and HLA-CFNx0101 (P = 0.0304) in AML when compared with control individuals. In contrast, the HLA-BFN*0139 and HLA-CFN*0107 allele frequency was higher in acute leukemia (P = 0.00372 and P = 0.0463, respectively) and in AML (P = 0.0010 and P = 0.0178, respectively) than that in controls. On multivariate analysis, BFNx0139 showed positive associations with acute leukemia (P = 0.006) and AML (P = 0.002). HLA-AFN*0111 and-DRB1FN*0111 showed a negative association with acute leukemia (P = 0.009 and P < 0.0001, respectively) and ALL (P = 0.013 and P < 0.0001, respectively). Conclusions: The HLA-BFN*0139 has a positive association with AML and acute leukemia, whereas HLA-AFN*0111 and HLA-DRB1FN*0111 alleles have negative association with ALL and HLA-BFN*0151 along with these two alleles with acute leukemia. No positive association was observed with ALL. HLA-CFN*0101 frequency was lower in AML patients than that in controls.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Vimarsh Raina

DOI: 10.3390/transplantology5020009

Volume5
Issue2
Pages85-97
Abstract

Histocompatibility testing is pivotal in any renal transplantation workup, aimed at enhancing prospective donor recipient compatibility and improving transplant outcomes. The evolution and advancement of histocompatibility testing, particularly HLA typing, have significantly improved its precision. This study outlines the historical progression from serologic to DNA-based HLA typing, emphasizing the role of HLA proteins in immune response. Anti-HLA antibodies, targeting HLA proteins, pose challenges in renal transplantation. Monitoring and managing these antibodies are critical for renal transplant success. Complement-dependent cytotoxicity crossmatch and flow cytometry crossmatch are essential techniques for assessing donor–recipient compatibility. Panel-reactive antibody assesses antibodies against a panel of donor antigens, often HLA. Higher PRA levels (percentage) complicate donor matching, requiring specialized protocols. Virtual crossmatch evaluates recipient anti-HLA antibodies against potential donors through synthetic beads. This approach predicts crossmatch outcomes by comparing antibody profiles, offering a valuable tool for the risk assessment of renal transplantation. Despite advancements, a comprehensive understanding of alloreactive immune responses requires a combination of assays, emphasizing the importance of a multifaceted approach in histocompatibility testing. This is an attempt to compile the relevant information, providing a basis for comparison in a clear and foundational format for histocompatibility testing laboratories.

Authors: Vikash Chandra Mishra, Vimarsh Raina

DOI: 10.14218/jctp.2023.00045

Volume4
Issue1
Pages12-17
Abstract

Our capacity to recognize and manage allosensitized transplant recipients and optimize organ allocation has been greatly improved by the development of single-antigen bead tests for detecting human leukocyte antigen antibodies. The main drawbacks of this technology have been thoroughly discussed in the literature, covering problems like artifacts that result in nonspecific background, variability, lack of uniformity, and difficulties in data interpretation. Consequently, it is not always easy to understand single-antigen bead data. This review will discuss the interpretation of donor-specific antibody data while considering the associated technical limitations. To ensure the correct clinical application of this test and to enhance the quality of antibody data used to support published clinical research in the era of epitope-based computational matching algorithms, a detailed understanding of the single-antigen bead assay is necessary.

Authors: Vikash Mishra

DOI: 10.55459/ijca/v2i1/vm

Volume2
Issue1
Pages52-55
Abstract

ISO15189:2012 is a formal recognition by an authorized national accreditation body that a testing laboratory is competent to carry out specific tasks according to the standard. This article aims to share the experience of reaching ISO 15189:2012 accreditation at Chimera labs. A gap analysis was performed, followed by the preparation and implementation of policies and procedures for the effective implementation of QMS. After six months of intensive work, including mentoring activities, the laboratory was ISO 15189 accredited in the field of medical genetics and related HLA and immunogenetics by the National Accreditation Board for Testing and Calibration Laboratories, India. Our experience suggests that the implementation of a quality management system is possible even in small-sized laboratories with the help of skilled manpower and supportive management.

Authors: Vikash Chandra Mishra, Anoushka Raina, Dinesh Chandra , Ritu Sharma, Amit Kr. Bhardwaj, Vimarsh Raina

DOI: 10.52547/vacres.8.2.112

Volume9
Issue1
Pages58-62
Abstract

Introduction: Since HLA-B*15:02 is a biomarker for carbamazepine-induced Stevens- Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in certain Asian populations, the United States food and drug administration (USFDA) recommends HLA-B*15:02 screening before carbamazepine administration in Asian and other communities. Several published reports across the globe suggested a strong association of HLA-B*15 with carbamazepine-induced hypersensitivity reactions. Methods: This study was conducted to estimate the prevalence and the genetic polymorphism of HLAB* 15 in the North Indian population (N=5469) by PCR sequence-specific oligonucleotide probe (SSOP) genotyping of the HLA-B locus. Results: The total allelic variants of HLA-B*15 identified amongst the studied samples were 17. The most frequent among these was HLA-B*15:17 (2.030%). Subsequently, HLA -B* 15:01 (1.463%) and B*15:02 (1.225%) were more frequent. Further, 185 HLA-B*15 genotypes were seen among the studied population with which the most frequent were HLA-B*15:17-40:06(0.402%), HLA-B*15:17-35:03 (0.366%) and HLA-B*15:02- 40:06 (0.347%). Conclusion: This information highlights the prevalence and diversity of HLA-B*15 genotyping and its importance in the screening of carbamazepineinduced SJS/TEN in the North Indian population where the prevalence of HLA-B*15 allelic variants was on the higher side. Further, this baseline information could be further explored in the understanding of the pathogenesis of the disease and may contribute valuable information for designing effective vaccines and clinical trials.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Anoushka Raina, Ritu Sharma, Vimarsh Raina

DOI: 10.69709/genomc.2024.193514

Volume1
Issue1
Pages1-6
Abstract

Introduction: Numerous studies have concentrated on specific populations to explore the extensive polymorphism of class I and II HLA genes. This genetic diversity is crucial for various applications, such as advancing transplantation immunology, understanding genetic population patterns, and uncovering the pathways of different diseases. Objective: The objective of the present study was to determine and analyse the frequencies of class I (HLA-A, HLA-B and, HLA-C), and class II (HLA-DRB1, and HLA-DQB1) genes in the North Indian population. Material and Methods: To achieve the objective of the study, buccal swab samples from 3,648 individuals were collected. All these samples were subsequently tested for the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 genes using the polymerase chain reaction (PCR) sequence-specific oligonucleotide probe (SSOP) typing method and typing result were analyzed to estimate class I and II allele frequencies. Results: In the present study, we have identified 16 different variants of HLA-A genes, 28 variants of HLA-B genes, 13 variations of HLA-C genes, 14 variants of HLA-DRB1 genes, and 6 variants of HLA-DQB1 genes. Furthermore, HLA-A*11, HLA-B*35, HLA-C*07, HLA-DRB1*15, and DQB1*06 were observed to be the most frequent alleles within the studied population. Discussion: The findings of the studied population highlights the variability exhibited by the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 genes in the North Indian population. Additionally, this also highlights the importance of testing and understanding the prevalence of these specific HLA genes in these populations, which has a greater relevance in both hematopoietic stem cell and solid organ transplantation as well as disease association studies.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Anoushka Raina, Avdhesh Pandey, Vimarsh Raina

DOI: 10.25259/ijms_131_2024

Volume0
Issue0
Pages1-5
Abstract

Objectives: Ankylosing spondylitis (AS) is a type of spondylitis in which the spine and other joints are largely affected. A strong association of HLA-B*27 with AS has been observed. However, the exact mechanism underlying this association and the pathogenesis of the disease remains unclear. As the diversity of HLA varies among populations, our objective was to investigate the prevalence of HLA-B*27 and its allelic variants in the North Indian population. Materials and Methods: The data of 7451 individuals were analyzed for the study and all these samples have HLA typed by sequence-based typing from an American Society for Histocompatibility and Immunogenetics (ASHI)-accredited laboratory. Results: Among the studied population, 304 individuals (4.08%) were found to have HLA-B* 27 allele. The most frequent subtypes of HLA-B*27 observed in the North Indian population were HLA-B*27: 05 (21.71%) and HLA-B*27: 07 (16.28%). A total of 97 HLA-B genotypes were identified among studied population. Conclusion: The higher frequency of HLA-B*27:05 suggests an idea that the North Indian population may have a higher risk of AS.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Anoushka Raina, Vimarsh Raina

DOI: 10.4103/ijcfm.ijcfm_24_24

Volume10
Issue2
Pages135-138
Abstract

Introduction: Hematopoietic stem cell transplantation (HSCT) is a crucial treatment for various blood disorders. However, the scarcity of matched related donors has led to the establishment of stem cell donor databases, commonly known as stem cell registries. These registries aim to streamline the identification of unrelated volunteer stem cell donors for matched unrelated donor HSCT. This study specifically aims to assess the level of knowledge and engagement among healthcare professionals in Delhi National Capital Region (NCR) regarding hematopoietic stem cell (HSC) donation. Material and Methods: The cross-sectional observational study involved 240 healthcare professionals was conducted in the Delhi. Results: The study findings indicate that the level of awareness about HSC and transplants among healthcare professionals was 44.25 and 40%, respectively, revealing a substantial knowledge gap in this field. Surprisingly, none of the participants reported prior experience with stem cell donation. However, a noteworthy 70.4% expressed a willingness to be part of the stem cell registry. Conclusion: The study emphasizes the urgent need for comprehensive education and awareness initiatives, especially targeting healthcare professionals, to bridge the knowledge gap and boost volunteer stem cell donor registrations for the benefit of patients requiring HSCT. The results serve as a foundation for fostering a more informed and engaged community in the field of HSCs, underscoring the importance of proactive measures to enhance knowledge and participation.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Ritu Sharma, Avdhesh Pandey, Vimarsh Raina

DOI: 10.4103/ijot.ijot_76_24

Volume19
Issue1
Pages58-63
Abstract

Background: Mitochondrial DNA (mtDNA) typing, based on nucleotide sequencing of the control regions (known as hypervariable Regions I and II), is utilized in forensic investigations, human migration studies, and population genetics research. The objective of this study is to estimate mitochondrial haplogroup distribution and frequencies among the North Indian population using an appropriate statistical tool. Materials and Methods: In this study, a total of 230 samples were included and analyzed using polymerase chain reaction, gel detection, and Sanger sequencing methodologies from the region of North India. Results: A total of 63 distinct haplogroups were identified. Among these, haplogroup M was the most prevalent (38.26%), followed by haplogroup U (25.22%) and R (9.57%). The information obtained from this study will contribute to the development of a mtDNA database for the Indian population. Conclusion: This database could be valuable for forensic investigations, human migration studies, and population genetics research. It also suggests that mtDNA analysis would be useful for establishing maternal relationships in solid organ transplants, particularly in India.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Vimarsh Raina

DOI: 10.3390/transplantology6020009

Volume6
Issue2
Pages9
Abstract

Antibody-mediated rejection is a critical factor in acute and chronic allograft rejection, with Human Leukocyte Antigen as the primary target of the humoral immune response in kidney transplants. In addition to HLA antibodies, non-HLA Abs also play a significant role in AMR. These non-HLA Abs, which can target either autoantigens or alloantigens, may be present pre-transplantation or develop post-transplant. They are associated with various types of allograft injury. The major non-HLA Abs include those directed against the angiotensin II type 1 receptor, endothelin type A receptor, and MICA, as well as other antigens such as vimentin, collagens, and anti-endothelial cell antibodies. Factors such as ischemia, reperfusion injury, and calcineurin inhibitor toxicity can trigger the pathogenic activity of these Abs. The mechanisms underlying non-HLA Ab production are not yet fully understood but are thought to involve endothelial injury and the exposure of neoantigens. Research indicates that these non-HLA Abs can cause graft injury through both complement-dependent and complement-independent pathways. However, detecting non-HLA Abs remains a challenge due to the lack of reliable diagnostic tools. Current treatment strategies for managing the effects of pathogenic non-HLA Abs include intravenous immunoglobulin, plasmapheresis, rituximab, and bortezomib. Early identification of high-risk patients and timely intervention are crucial to preventing graft failure. This review examines the development, mechanisms, and clinical significance of non-HLA Abs in kidney transplantation, highlighting the need for improved diagnostic methods and tailored therapeutic approaches.

Authors: Vikash Mishra, Dinesh Chandra, Vimarsh Raina

DOI: 10.55459/ijca/v4i1/vm.dc.vr

Volume4
Issue1
Pages50-55
Abstract

Quality management (QM) is a critical component of laboratory services and has evolved significantly to improve the accuracy, reliability, and consistency of test results while meeting increasing demands for patient safety and regulatory compliance. This article highlights the historical development of quality management practices in laboratory settings, key milestones, and recent advancements, including the implementation of quality management systems, adherence to global (like ISO) standards, and the integration of technology to enhance both patient outcomes and operational efficiency.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Vimarsh Raina

DOI: 10.4103/ijot.ijot_23_25

Volume19
Issue3
Pages304-309
Abstract

Donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) is a promising noninvasive biomarker for monitoring organ transplant rejection and graft status as it is released into the recipient’s bloodstream due to graft injury, ischemia, or immune response. Various detection methodologies allow precise quantification, including polymerase chain reaction-based techniques, next-generation sequencing, and methylation-based assays. Despite its utility and potential, challenges remain a factor such as distinguishing dd-cfDNA from recipient cell-free DNA and standardization of methods. Clinically, dd-cfDNA enhances early graft rejection detection and subsequently guides immunosuppressive therapy. In addition, dd-cfDNA reduces the dependence on biopsies. Further, advancements in sequencing and bioinformatics refine its role in monitoring organ transplant rejection and graft status.

Authors: Mishra VC, Chandra D, Sharma R, Dhuliya D, Raina V.

DOI: 10.3390/transplantology6040034

Volume6
Issue4
Pages34
Abstract

Background/Objectives: Epitope-based matching has emerged as a refined approach for assessing donor–recipient compatibility in renal transplantation. However, limited data are available on HLA Class I epitope distribution among Indian patients, particularly from northern India, where substantial allelic diversity is known to influence immunological risk. Methods: This retrospective analysis evaluated HLA Class I single-antigen bead (SAB) antibody data from 218 consecutive renal-transplant candidates who tested positive for anti-HLA antibodies between July 2018 and September 2024. HLA Class I epitopes were identified and analyzed using MATCH IT Antibody Software (Immucor, version 1.5.0). Demographic variables and sensitization history (previous transplant, transfusion, pregnancy) were reviewed. Results: A total of 504 distinct epitopes were identified, with 65GK and 163LG emerging as the most frequent motifs. The predominance of these epitopes mirrors the high prevalence of alleles such as HLA-A*24 and HLA-B*35 reported in North-Indian populations. The data suggest a strong influence of regional allele architecture on the immunogenic epitope landscape. Conclusions: This study provides the first baseline characterization of HLA Class I epitope distribution among northern-Indian renal-transplant candidates. The findings emphasize the need for establishing population-specific HLA epitope databases and highlight the potential of epitope-based matching to enhance donor selection and minimize immunological risk in Indian transplantation programs.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Vimarsh Raina

DOI: 10.21926/obm.transplant.2504260

Volume9
Issue4
Pages1-12
Abstract

Though the role of clinical histocompatibility testing is fundamental to successful transplant, systematic risk assessment and mitigation strategies remain underutilised in this domain. This review addresses risk identification, analysis, and control measures across the pre-analytical, analytical, and post-analytical phases of clinical histocompatibility testing, in line with international standards such as ISO 15189:2022. A structured, risk-based quality management system (QMS) is imperative for ensuring accurate testing, timely reporting, and subsequently optimal transplant outcomes. Future directions include leveraging digital tools and fostering a culture of continuous improvement in histocompatibility laboratories.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Ritu Sharma, Vimarsh Raina

DOI: 10.4103/ijot.ijot_45_25

Volume19
Issue4
Pages509-511
Abstract

Histocompatibility testing plays an important role in the success of renal transplantation outcome by ensuring optimal donor recipient compatibility. Developments in testing methods have increased transplant success, but discrepancies between different tests can sometimes make it harder to make the best clinical decisions. We report a case of a renal transplant patient whose single antigen bead test showed donor-specific antibody against HLA-DRB1*11:04 and HLA-DRB1*14:04, but the CDCXM and FCXM tests were negative. A review of the literature showed that the patient’s homozygosity for HLA-DRB1*07 could explain the negative crossmatch due to epitope-specific (25R) antibody reactivity. This case highlights the need for using multiple tests and considering epitope-level assessment in improving transplant decision-making.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Vimarsh Raina

DOI: 10.4103/ijot.ijot_115_25

Volume20
Issue1
Pages17-22
Abstract

Histocompatibility testing is pivotal to the transplantation process since it helps determine immune compatibility between donors and recipients. This compatibility reduces the risk of rejection and improves transplant outcomes. Errors in this testing can have serious consequences for patients and affect the survival of the graft. Therefore, maintaining a robust quality control (QC) system is essential. However, keeping robust QC standards in histocompatibility testing faces several challenges. These challenges arise from the diverse nature of human leukocyte antigens genes, advances in technology, and the lack of consistent interpretation standards among different laboratories. This review aims to compile current practices in QC in histocompatibility testing, including internal QC, external quality assurance, accreditation systems, and common challenges.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Vimarsh Raina

DOI: 10.55459/ijca/v5i1/vm.dc.vr

Volume5
Issue1
Pages48-52
Abstract

External quality assessment (EQA) is an important tool in laboratory services, ensuring the accuracy, reliability, and consistency of diagnostic test results. In an EQA program, an external body distributes unknown samples to participating laboratories, which analyze them and report their results for comparison with those of peer institutions. This process enables laboratories to identify errors, monitor performance trends, and implement corrective measures. This article outlines the concept, process, importance, and challenges of EQA and highlights its role in supporting patient safety and healthcare quality.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Anoushka Raina, Ritu Sharma, Diksha Dhuliya, Vimarsh Raina

DOI: 10.69709/genomc.2026.157570

Volume5
Issue3
Pages0024
Abstract

Y-chromosomal short tandem repeats (Y-STRs) are passed from father to son through the male line only. They change very little over generations and are widely used in forensic science and for tracing paternal ancestry. However, mutations at Y-STR loci can complicate relationship analyses, and may result in inaccurate exclusions during father-son or extended paternal lineage testing. . In this preliminary study, we looked for possible Y-STR mutations in 292 cases from the North Indian population. These cases included pairs of siblings, uncles and nephews, first cousins, and second cousins. We found a total of 29 mutations across 11 Y-STR markers out of 16 markers. All mutations were single-step changes consistent with the stepwise mutation model. The highest mutation rates were at DYS458 (0.006) and DYS385 (0.005), while loci such as DYS19, DYS390, and DYS389II had lower rates (0.001). These results align with previous findings on mutation rates at different loci. They also support the observation that Y-STRs with rapid mutations provide better information for distinguishing closely related paternal lineages. Our findings give baseline estimates of mutation rates for the North Indian populace, highlighting the need for population-specific data in forensic work and genealogical research.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Vimarsh Raina

DOI: 10.25259/ijms_28_2025

Volume0
Issue1
Pages1-5
Abstract

To promote accuracy, reliability, and patient safety in laboratory diagnostics, the International Organization for Standardization (ISO) 15189 has been established as an important standard for medical laboratories worldwide, ensuring that they meet stringent laboratory quality requirements. Despite this, its implementation is not an easy task and presents challenges such as the resource-intensive nature of ISO15189 adoption, training gaps, and resistance to change in many regions, particularly in low-resource settings, when incorporating a unified approach to laboratory quality management system (QMS). The risk-based thinking, patient-centered care, and standard flexibility have allowed laboratories to adopt new technologies such as automation and digital platforms to enhance accuracy, efficiency, and patient care. Furthermore, integration with regulatory frameworks has facilitated harmonization across different countries, resulting in a more consistent approach to laboratory quality systems. The future of ISO 15189 is characterized by an increasing focus on collaborative efforts, the digital revolution of laboratories, sustainability, and proactive risk management. This is an attempt to analyze the current scenario of QMS in the context of ISO 15189, focusing on its implementation, challenges, and future directions to make ISO 15189 more accessible to laboratories globally.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Vimarsh Raina

DOI: 10.21926/obm.transplant.2603272

Volume10
Issue3
Pages1-13
Abstract

Hematopoietic stem cell transplantation (HSCT) offers a potentially curative option for a range of malignant and non-malignant hematological disorders. However, only approximately 25-30% of patients have access to a human leukocyte antigen (HLA)-matched related donor (MRD), necessitating alternative donor approaches, including matched unrelated donor (MUD) and haploidentical transplantation. Although advances in haploidentical HSCT have substantially improved donor availability, MUD HSCT continues to play an important role in selected high-risk hematological malignancies where optimal HLA matching may influence transplant outcomes. Volunteer stem cell donor registries (VSCDRs) were established to address this unmet need and have evolved into a globally interconnected network facilitating international donor searches and cross-border hematopoietic stem cell (HSC) exchange. According to recent World Marrow Donor Association (WMDA) reports, the global donor pool exceeds 44 million volunteer donors and 0.76 million cord blood units (CBUs). Despite this expansion, significant disparities persist for genetically diverse and underrepresented populations, particularly in South Asia. India faces unique challenges related to extensive HLA heterogeneity, limited indigenous donor representation, prolonged MUD search timelines, and donor attrition. Recent studies suggest that fully MUD probabilities for Indian patients remain substantially lower than those reported for populations of European ancestry. This review summarizes the global evolution of VSCDRs, examines the current landscape of Indian registries, and discusses key operational, economic, and infrastructural challenges affecting MUD HSCT in India. Potential strategies, including targeted donor recruitment, improved donor retention programs, national registry integration, and broader adoption of next-generation sequencing (NGS)-based high-resolution (HR) HLA typing, are also discussed as approaches to improve donor availability and equitable access to HSCT in India.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Anoushka Raina, Ritu Sharma, Diksha Dhuliya, Vimarsh Raina

DOI: 10.1016/j.legalmed.2026.102996

Volume86
Issue102996
Pages102996
Abstract

Triallelic patterns at autosomal short tandem repeat (STR) loci are uncommon findings in forensic genetics but may complicate the interpretation of parentage and kinship analyses. In this retrospective study, we reviewed 15,000 consecutive autosomal STR profiles generated during routine parentage testing between January 2019 and July 2025 to characterize the occurrence and distribution of triallelic STR patterns in an Indian parentage-testing dataset. Fifteen STR profiles exhibited triallelic patterns, corresponding to an observed profile-level proportion of 0.1%. Triallelic patterns were detected at six STR loci: D21S11 (n = 7), D1S1656 (n = 3), D10S1248 (n = 2), and one case each at TPOX, CSF1PO, and D3S1358. Type II patterns predominated (10/15, 66.7%), whereas Type I patterns accounted for 5/15 (33.3%). Among the 15 triallelic-positive profiles, the corresponding parentage investigations comprised 7 maternity duo investigations, 6 paternity duo investigations, and 2 trio investigations. These findings highlight the importance of recognizing and appropriately interpreting triallelic STR patterns during routine parentage testing and provide additional reference data from an Indian parentage-testing dataset.

Authors: Vikash Chandra Mishra, Dinesh Chandra, Vimarsh Raina

DOI: 10.4103/ijot.ijot_11_26

Volume20
Issue3
Pages296-302
Abstract

In histocompatibility and immunogenetics (H and I) laboratories, testing accuracy directly affects patient selection, donor-recipient matching, organ allocation, and post-transplant outcomes. Assessing competency is crucial for maintaining quality control in laboratory services. The complexity and rapid advancement in human leukocyte antigen typing, antibody testing, and crossmatch methodologies require structured, validated approaches to evaluating laboratory personnel competency. This is an attempt to bring together current practices, regulatory expectations, available assessment tools, and emerging innovations in H and I laboratory services for competency assessment.

No matching articles

Try another word from the title, author or DOI.

Brief Bio

Over 15 years of experience in histocompatibility, DNA profiling, and laboratory quality management and accreditation.

Affiliations

Nothing added yet.

Education

Nothing added yet.

Honors & Awards

Nothing added yet.

Society Memberships

Nothing added yet.

Expertise

Nothing added yet.

Specialty

Nothing added yet.

Suggested researchers

SA
Shaik Ali Hassan
Bhabha College of Dental Sciences, Bhopal, Madhya Pradesh, India
55 publications
Girendra Kumar Gautam
Shri Ram College of Pharmacy, Muzaffarnagar
63 publications
Fathi M Sherif
University of Tripoli, Pharmacy, Pharmacology
31 publications
AN
Akshaya Narayan Shetti
Dr. Balasaheb Vikhe Patil Rural Medical College, Loni, Maharashtra, India
22 publications
VY
Varun Yadav
, Indore, Madhya Pradesh, India
15 publications
Madhur Gupta
NKP Salve Institute of Medical Sciences & Research Centre and Lata Mangeshkar Hospital, Nagpur, Maharashtra, India
105 publications
DK
Dinesh Kansal
D
20 publications
AK
ANANDRAJ K C
Madurai Kamaraj University
16 publications
MS
Mahesh Shivananjappa
16 publications
Abhijeet Dawle
SVKM's NMIMS, MPSTME, Shirpur, Dist Dhule, Maharashtra, India
28 publications
Somchai Amornyotin
Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University
108 publications
SS
S S Jha
I
16 publications

Following

Nobody here yet.

Followers

Nobody here yet.

58 Publications